INFLUENCE OF SUBTLE ENERGETIC CHANGE IN WATER ON THE HUMAN ENERGY STATE

The normal functioning of an organism depends on water and its properties. The role of the water is vital for human life. Most important is that the water should not only be safe, but also well suited for constant daily use, rendering beneficial effect on the organism. In the present work different types of water were used to determine its influence on the quality of life. The quality of life was measured using the Profile of Mood State (POMS) questionnaire. The Gas Discharge Visualization (GDY) method was applied during six weeks to people drinking their usual water, during the next six weeks when mineral water was used, and the last six weeks when the same mineral water was taken but after subtle energetic changes at the natural energetic deposit [BAE (Bio Active Energy) Synergy Liquid]. Significance of results was assessed by the Wilcoxon and sign statistical tests. After using BAE Synergy Liquid, a statistically significant decrease was obtained for the following POMS parameters: tension-anxiety, depressiondejection, anger-hostility, fatigue-inertia, and confusion-bewilderment. At the same time, forceactivity parameter was increased, as well as GDV parameters: Area and Intensity under normalization of GDV Activation. The use of mineral water which underwent subtle energetic changes at the energetic deposit (BAE Synergy Liquid) reduces anxiety and aggression, raises emotional tone, and also raises the general energetic state of the organism. The GDV method also discloses statistically significant distinctions between mineral water and mineral water which underwent subtle energetic changes at the energetic deposit while its chemical structure remains the same

INFLUENCE OF SUBTLE ENERGETIC CHANGE IN WATER ON THE HUMAN ENERGY STATE

The normal functioning of an organism depends on water and its properties. The role of the water is vital for human life. Most important is that the water should not only be safe, but also well suited for constant daily use, rendering beneficial effect on the organism. In the present work different types of water were used to determine its influence on the quality of life. The quality of life was measured using the Profile of Mood State (POMS) questionnaire. The Gas Discharge Visualization (GDY) method was applied during six weeks to people drinking their usual water, during the next six weeks when mineral water was used, and the last six weeks when the same mineral water was taken but after subtle energetic changes at the natural energetic deposit [BAE (Bio Active Energy) Synergy Liquid]. Significance of results was assessed by the Wilcoxon and sign statistical tests. After using BAE Synergy Liquid, a statistically significant decrease was obtained for the following POMS parameters: tension-anxiety, depressiondejection, anger-hostility, fatigue-inertia, and confusion-bewilderment. At the same time, forceactivity parameter was increased, as well as GDV parameters: Area and Intensity under normalization of GDV Activation. The use of mineral water which underwent subtle energetic changes at the energetic deposit (BAE Synergy Liquid) reduces anxiety and aggression, raises emotional tone, and also raises the general energetic state of the organism. The GDV method also discloses statistically significant distinctions between mineral water and mineral water which underwent subtle energetic changes at the energetic deposit while its chemical structure remains the same

The sleep quality of patients with insomnia under the influence of subtle energy fields

Background: The article evaluates the current state of insomnia treatment for patients without neurological, psychiatric, and somatic disorders. An important goal consists in developing non-drug therapies for insomnia, possessing no side effects. Following this research direction, we put a special emphasis on non-medicamental methods for correction of sleep disturbance in persons with psychophysiological insomnia.Methods: Authors propose a method of insomnia treatment in which patients sleep on the specialized Bio Velocity mattresses (the ‘activated mattress’ therapy). The conditions of patients before and after the treatment are assessed by clinical, psychophysiological, electroencephalographic methods, and by the Voll method, which studies the meridians of organs and systems, including the nervous system.Results: We show the effectiveness of the therapy by demonstrating improving psychological indicators, EEG data, and the Voll diagnostics data in a group of patients.Conclusions: The activated Bio Velocity mattresses can effectively be used by patients with the sleep disorders in addition to and, partially, as a replacement of conventional tools and medicine.

Breast state improvement by using the lymphatic drainage disposable bra pads

Background: The health and good esthetic conditions of the breast are important indicators of women’s life quality. One factor that negatively affects this quality is the breast ptosis, associated with the sagging of the mammary glands due to tissue stretching and the loss of tissue and skin elasticity. New tools and methods able to improve the shape and beautiful contour of the breast are highly desirable.Methods: We investigated how the disposable bra pads by BAE International Inc., having the lymphatic drainage effect for the breast, influenced the female breast state. We applied two methods, the ultrasound elasticity imaging and the pattern recognition of the nipples position, to monitor the breast state dynamics in two groups of females, the study and control ones.Results: Preliminary results showed that both the breast elasticity and the pattern of nipple positions improved for females wearing the bra pads as compared to females wearing regular bras without pads (P<0.05 for the difference between the two groups of females).Conclusions: Overall, the bra pads by BAE can be considered as an effective tool encouraging metabolism by improving the flow of blood circulation and lymph in the breast

A cohort survey of the effect of an educational intervention on human papillomavirus vaccine-related knowledge and attitudes among pre-university female students in Singapore

Introduction: Although cervical cancer is the 10th most common cancer among females in Singapore, it is a vaccine-preventable cancer. Human papillomavirus vaccines combined with regular Pap (papillomavirus) smears have been shown to reduce the mortality and morbidity associated with cervical cancer. We assessed the knowledge and attitudes towards cervical cancer, human papillomavirus and its vaccination amongst pre-university female students and assessed if a short educational presentation can improve this knowledge and acceptability of the vaccine. Methods: A cohort survey was carried out amongst 150 female students at Hwa Chong Junior College via questionnaires administered anonymously. Standardized educational presentations were carried out followed by post intervention questionnaires. Results: Almost all the students were aged between 15 and 19 years old (99.3%). At baseline, only 29% and 27% of the students had ever heard of human papillomavirus and its vaccines respectively. The most common source of information cited was from a family member or a friend (22.5%). Only 4% had been administered the human papillomavirus vaccine. Mean knowledge scores significantly improved from 4.95 to 8.61 out of 10 after the intervention. Of those who did not have the vaccine, only 31.3% were willing to consider the human papillomavirus vaccine pre-intervention, with a statistically significant improvement to 51.4% post intervention. Conclusion: Low awareness about human papillomavirus, its relationship to cervical cancer and its prevention is common, even amongst well-educated students. Most of them obtained the information from family and/or friends. A short educational presentation was able to improve the knowledge scores, and improve the acceptability of the human papillomavirus vaccine

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.Methods: KEYNOTE-966 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 175 medical centres globally. Eligible participants were aged 18 years or older; had previously untreated, unresectable, locally advanced or metastatic biliary tract cancer; had disease measurable per Response Evaluation Criteria in Solid Tumours version 1.1; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to pembrolizumab 200 mg or placebo, both administered intravenously every 3 weeks (maximum 35 cycles), in combination with gemcitabine (1000 mg/m2 intravenously on days 1 and 8 every 3 weeks; no maximum duration) and cisplatin (25 mg/m2 intravenously on days 1 and 8 every 3 weeks; maximum 8 cycles). Randomisation was done using a central interactive voice-response system and stratified by geographical region, disease stage, and site of origin in block sizes of four. The primary endpoint of overall survival was evaluated in the intention-to-treat population. The secondary endpoint of safety was evaluated in the as-treated population. This study is registered at ClinicalTrials.gov, NCT04003636.Findings: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]). In the as-treated population, the maximum adverse event grade was 3 to 4 in 420 (79%) of 529 participants in the pembrolizumab group and 400 (75%) of 534 in the placebo group; 369 (70%) participants in the pembrolizumab group and 367 (69%) in the placebo group had treatment-related adverse events with a maximum grade of 3 to 4. 31 (6%) participants in the pembrolizumab group and 49 (9%) in the placebo group died due to adverse events, including eight (2%) in the pembrolizumab group and three (1%) in the placebo group who died due to treatment-related adverse events.Interpretation: Based on a statistically significant, clinically meaningful improvement in overall survival compared with gemcitabine and cisplatin without any new safety signals, pembrolizumab plus gemcitabine and cisplatin could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer